用重组LD1抗原进行免疫可预防实验性利什曼病。
Immunization with recombinant LD1 antigens protects against experimental leishmaniasis.
作者信息
Dole V S, Raj V S, Ghosh A, Madhubala R, Myler P J, Stuart K D
机构信息
School of Life Science, Jawaharlal Nehru University, New Delhi 110 067, India.
出版信息
Vaccine. 2000 Oct 15;19(4-5):423-30. doi: 10.1016/s0264-410x(00)00207-3.
The genes, ORFF and BT1 (previously ORFG), are part of the multigenic LD1 locus on chromosome 35 which is frequently amplified in Leishmania. BT1 encodes a biopterin transporter, while the function of the ORFF gene product is unknown, but it is localized to the nucleus. We show here that immunization of mice with recombinant ORFF and BT1 proteins, individually, or in combination, conferred partial protection against challenge with Leishmania donovani. Protection correlated with the production of antigen-specific antibodies and in vitro splenocyte proliferation. Thus, these antigens can be potential vaccine candidates against visceral leishmaniasis.
基因ORFF和BT1（以前称为ORFG）是35号染色体上多基因LD1位点的一部分，该位点在利什曼原虫中经常扩增。BT1编码一种生物蝶呤转运蛋白，而ORFF基因产物的功能尚不清楚，但它定位于细胞核。我们在此表明，用重组ORFF和BT1蛋白单独或联合免疫小鼠，可对杜氏利什曼原虫攻击提供部分保护。保护作用与抗原特异性抗体的产生和体外脾细胞增殖相关。因此，这些抗原可能是抗内脏利什曼病的潜在疫苗候选物。
Zotero 插件